Page last updated: 2024-12-05

cephaloridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cephaloridine: A cephalosporin antibiotic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5773
CHEMBL ID316157
CHEBI ID3537
SCHEMBL ID3936
SCHEMBL ID23270209
MeSH IDM0003824

Synonyms (93)

Synonym
CHEMBL316157
(6r,7r)-8-oxo-3-(pyridinium-1-ylmethyl)-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
hsdb 3023
lloncefal
ceporan
ceporine
cephaloridin
lilly 40602
ampligram
7-(thiophene-2-acetamido)-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid betaine
ceflorin
keflodin
deflorin
cefaloridinum [inn-latin]
kefspor
ceph 87/4
cephalomycine
intrasporin
n-(7-(2'-thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate
ceporin
einecs 200-052-6
7-(alpha-(2-thienyl)acetamido)-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid betaine
vioviantine
sch 11527
faredina
pyridinium, 1-((2-carboxy-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-trans)-
cefalorizin
cepalorin
cepaloridin
(6r,7r)-1-((2-carboxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt
cilifor
pyridinium, 1-((2-carboxy-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-en-3-yl)methyl)-, hydroxide, inner salt, (6r-trans)-
glaxoridin
keflordin
sasperin
sefacin
cefaloridin
verolgin
7-((2-thienyl)acetamido)-3-(1-pyridylmethyl)cephalosporanic acid
1-((7'-beta-(2-(2-thienyl)acetamido)-8'-oxo-1'-aza-5'-thiabicyclo(4.2.0)-oct-2'-en-3'-yl)methyl)pyridinium-2'-carboxylate
cephaloridinum
betaine cephaloridine
aliporina
pyridinium, 1-((2-carboxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt
cefaloridina [inn-spanish]
n-(7-((2-thienyl)acetamido)ceph-3-em-3-ylmethyl)pyridinium-4-carboxylate
CER ,
cephaloridine
50-59-9
cefaloridine
7-[.alpha.(2-thienyl)-acetoamido]-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid betaine
(6r,7r)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[[2-(2-thienyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
kefloridin
loridine
D01075
cefaloridine (jan/inn)
kefloridin (tn)
cephaloridine (usan)
NCGC00094956-01
cefaloridina
CHEBI:3537 ,
3-(pyridinium-1-ylmethyl)-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate
cefaloridinum
(6r,7r)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
dtxsid9022782 ,
tox21_111368
cas-50-59-9
dtxcid802782
AKOS016014429
cefaloridine [inn]
unii-lvz1vc61hb
cephaloridine [usan:usp]
lvz1vc61hb ,
EPITOPE ID:120366
cefaloridine [mart.]
7-(.alpha.-(2-thienyl)acetamido)-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid betaine
((6r,7r)-1-((2-carboxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt
cephaloridine [hsdb]
cephaloridine [mi]
cefaloridine [jan]
cephaloridine [usan]
cefaloridine [who-dd]
SCHEMBL3936
CZTQZXZIADLWOZ-CRAIPNDOSA-N
DB09008
(6r,7r)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)- 7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylate
bdbm50103624
Q5063323
SCHEMBL23270209
(6r,7r)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
gtpl12189
HY-B2072
CS-0017449

Research Excerpts

Overview

Cephaloridine is a zwitterion and its accumulation in renal cortex has been suggested to be regulated by both organic anion and cation transport systems. It is a semi-synthetic broad-spectrum bactericidal antibiotic derived from cephalosporin C.

ExcerptReferenceRelevance
"Cephaloridine (CER) is a classical beta-lactam antibiotic that has long served as a model drug for the study of cephalosporin antibiotic-induced acute tubular necrosis. "( Transcriptomic analysis of nephrotoxicity induced by cephaloridine, a representative cephalosporin antibiotic.
Araki, A; Fujisawa, K; Fukushima, R; Furukawa, N; Ishizaki, J; Itoh, F; Kato, I; Okada, M; Omi, K; Rokushima, M; Torii, M; Yanagimoto, T, 2008
)
2.04
"Cephaloridine is a zwitterion and its accumulation in renal cortex has been suggested to be regulated by both organic anion and cation transport systems."( Effect of piperonyl butoxide on organic anion and cation transport in rabbit kidneys.
Hook, JB; Kuo, CH; Tune, BM, 1983
)
0.99
"Cephaloridine is a semi-synthetic broad-spectrum bactericidal antibiotic derived from cephalosporin C. "( Effect of cephaloridine on human chromosomes in vitro in lymphocyte cultures.
Ahuja, YR; Jaju, M, 1982
)
2.11
"Cephaloridine is an antibiotic well known for its remarkable efficacy and absence of ocular toxicity. "( [The ocular toxicity of cephaloridine - A clinical and experimental study (author's transl)].
Malthieu, D; Turut, P, 1980
)
2.01
"Cephaloridine (Cld) is a nephrotoxic cephalosporin antibiotic. "( Cephaloridine-induced renal pathological and biochemical changes in female rabbits and isolated proximal tubules in suspension.
Engelhardt, J; Heim, RA; Ponsler, GD; Rush, GF, 1992
)
3.17

Effects

Cephaloridine (CER) has been used to elucidate the mechanisms of cephalosporin antibiotic-induced nephrotoxicity. It has been shown to possess certain favorable pharmacologic features while retaining the desirable antimicrobial properties of the parent compound.

ExcerptReferenceRelevance
"Cephaloridine (CER) has been used to elucidate the mechanisms of cephalosporin antibiotic-induced nephrotoxicity. "( Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
Endou, H; Hosoyamada, M; Kanai, Y; Sekine, T; Takeda, M; Tojo, A, 1999
)
2
"Cephaloridine has been shown to possess certain favorable pharmacologic features while retaining the desirable antimicrobial properties of the parent compound, cephalothin. "( Excretion of cephaloridine and cephalothin in patients with renal impairment.
Atuk, N; Kunin, CM, 1966
)
2.06
"Cephaloridine has some renal toxic effects in high concentration; in the renal failure it is advisable to calculate the exact dose of the antibiotic by the use of nomograms when the creatinine clearance is known."( [Antibiotic therapy and renal insufficiency. Pharmacokinetics of pivampicillin, cephaloridin and streptomycin in chronic uremic patients undergoing conservative or hemodialytic treatment].
Bertoli, M; Campanacci, L; Cancarini, GC; Huber, W; Toigo, G, 1975
)
0.98
"Cephaloridine has been shown to produce both oxidative and mitochondrial respiratory injury in renal cortex in patterns of dose (or concentration) and time that are consistent with pathogenicity."( Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin.
Fravert, D; Hsu, CY; Tune, BM, 1989
)
1.21

Treatment

Cephaloridine treatment of the DIC group was associated with increased BUN levels, proteinuria and diminished renal cortical slice accumulation of organic cations. Treatment with cephal oridine alone produced a dose-related increase in urinary MDA and total porphyrin levels up to 1.6 and 7 times control values, respectively.

ExcerptReferenceRelevance
"Cephaloridine treatment of the DIC group was associated with increased BUN levels, proteinuria and diminished renal cortical slice accumulation of organic cations."( Cephaloridine nephrotoxicity in diabetic rats: modulation by insulin treatment.
Ball, JG; Valentovic, MA, 1995
)
2.46
"Treatment with cephaloridine alone (10-500 mg/kg, i.p.) produced a dose-related increase in urinary MDA and total porphyrin levels up to 1.6 and 7 times control values, respectively."( Urinary porphyrins as biological indicators of oxidative stress in the kidney. Interaction of mercury and cephaloridine.
Miller, DM; Woods, JS, 1993
)
0.84

Toxicity

Cephaloglycin (Cgl) and cephaloridine (Cld) are acutely toxic to the proximal renal tubule. Their intracellular attack on the mitochondrial transport and oxidation of tricarboxylic acid (TCA) cycle anionic substrates.

ExcerptReferenceRelevance
"Probenecid, when administered sc to F344 rats 1 hour prior to an iv LD50 dose of cis-dichlorodiammineplatinum(II) (CDPP), reduced significantly the peak BUN and serum creatinine levels which occurred 4 days following CDDP."( Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.
Gale, GR; Ross, DA, 1979
)
0.26
" Thus, some instances of cephalothin nephropathy appear to be toxic in nature with a histologic picture of acute tubular necrosis, whereas others exhibit signs of hypersensitivity including rash, eosinophilia, and interstitial nephritis."( The nephrotoxicity of cephalosporins: an overview.
Barza, M, 1978
)
0.26
" Calcium channel blockers have ameliorated tissue injury due to toxic and ischemic insults."( Effect of verapamil on cephaloridine nephrotoxicity in the rabbit.
Browning, MC, 1990
)
0.59
" We conclude that cephaloridine and cephaloglycin are both toxic to mitochondrial substrate uptake and respiration, but differ significantly in their generation of products of oxidation."( Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin.
Fravert, D; Hsu, CY; Tune, BM, 1989
)
0.82
"Nephrotoxicity of cefodizime sodium (THR-221), a new cephem antibiotic, was studied in rats by comparing its toxic effect with those of other cephem antibiotics including cephaloridine (CER), cefazolin (CEZ) and cefmetazol (CMZ)."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.47
" In order to evaluate the importance of the different factors causing toxic effects, the authors studied the correlations between toxicity and antibiotic concentration and between toxicity and period of contact."( Toxic effects of some antibiotics on rabbit kidney cells.
Eandi, M; Santiano, M; Viano, I, 1983
)
0.27
" Finally, we evaluated the effect of piperonyl butoxide on the nephrotoxicity of cephaloglycin, a more toxic cephalosporin that lacks the thiophene side-ring proposed as the target of MFO activation in earlier studies with cephaloridine."( Effects of piperonyl butoxide on cephalosporin nephrotoxicity in the rabbit. An effect on cephaloridine transport.
Fravert, D; Hook, JB; Hsu, CY; Kuo, CH; Tune, BM, 1983
)
0.67
"Prevention of cephalosporin nephrotoxicity in animal models by probenecid or p-aminohippurate requires treatment regimen that produce sustained inhibition of cortical accumulation of the toxic antibiotic."( Prevention of cephalosporin nephrotoxicity by other cephalosporins and by penicillins without significant inhibition of renal cortical uptake.
Browning, MC; Fravert, D; Hsu, CY; Tune, BM, 1982
)
0.26
" The present report describes the effects of transient ureteral obstruction, which increases intracellular concentrations of secreted organic anions, on the cortical uptake and the proximal tubular toxicity of several cephalosporins given in mildly toxic doses."( Effects of ureteral obstruction on the toxicity of cephalosporins in the rabbit kidney.
Hsu, CY; Prime, DJ; Tune, BM; Wang, PL, 1982
)
0.26
" The classification of proximal tubules in sections by television analysis on the basis of alkaline phosphatase reaction product concentration appears to be a reliable measure for detecting and quantifying toxic effects on proximal tubules of kidney."( Quantification of nephrotoxicity in rabbits by automated morphometry of alkaline phosphatase stained kidney sections.
Wachsmuth, ED, 1981
)
0.26
" CPH-only treated rats had severe toxic nephrosis characterised by acute tubular necrosis, and elevated blood urea and creatinine."( Glucocorticoid amelioration of nephrotoxicity: a study of cephaloridine-methylprednisolone interaction in the rat.
Cockburn, A; Everett, DJ; Garcia Conesa, MT; Harvey, PW; Healing, G; Major, IR; McFarlane, M; Olatunde, O; Purdy, KA, 1995
)
0.54
"Cephaloglycin (Cgl) and cephaloridine (Cld) are acutely toxic to the proximal renal tubule, in part because of their cellular uptake by a contraluminal anionic secretory carrier and in part through their intracellular attack on the mitochondrial transport and oxidation of tricarboxylic acid (TCA) cycle anionic substrates."( Toxicity of cephalosporins to fatty acid metabolism in rabbit renal cortical mitochondria.
Hsu, CY; Tune, BM, 1995
)
0.6
" Cld has little or no in vivo toxicity to mitochondrial butyrate metabolism, whereas in vivo Cgl is as toxic as Cld to respiration with PCarn."( Toxicity of cephalosporins to fatty acid metabolism in rabbit renal cortical mitochondria.
Hsu, CY; Tune, BM, 1995
)
0.29
" We administered three fourth of LD50 of each agent to male Fischer 344 rats, intra-peritoneally."( [Study on gamma-GTP activity in urine and renal tissue of drug-induced nephrotoxicity in rats].
Furuta, N; Nakada, J, 1993
)
0.29
" Consistent with the data in the literature concerning the mechanism of CLD accumulation in renal cells, our results show that CLD was more toxic when it was added at the basolateral than at the apical side of the cultured cells."( Advantages of a two-chamber culture system to test drug nephrotoxicity: the example of cephaloridine.
Baverel, G; Bolon, C; Gauthier, C; Simonnet, H, 1997
)
0.52
" In the present study, we analyzed gene expression profiles in the kidney of rats given subtoxic and toxic doses of CER to identify gene expression alterations closely associated with CER-induced nephrotoxicity."( Transcriptomic analysis of nephrotoxicity induced by cephaloridine, a representative cephalosporin antibiotic.
Araki, A; Fujisawa, K; Fukushima, R; Furukawa, N; Ishizaki, J; Itoh, F; Kato, I; Okada, M; Omi, K; Rokushima, M; Torii, M; Yanagimoto, T, 2008
)
0.6
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

The pharmacokinetic distribution of 10 cephalosporin compounds was reviewed in patients with various degrees of renal function. Using the values of serum levels obtained from this experiment, pharmacokinetics parameters were calculated. simulation curves of serum Levels for various doses and durations of cep Haloridine drip infusion were drawn.

ExcerptReferenceRelevance
"The pharmacokinetic distribution of 10 cephalosporin compounds, cephalothin, cephaloridine, cephaloglycine, cephalexin, cefazolin, cephapirin, cephradine, cephacentrile, cefoxitin, and cefamandole, in patients with various degrees of renal function was reviewed."( Pharmacokinetics of cephalosporins in patients with normal or reduced renal function.
Andriole, VT, 1978
)
0.49
" The effects of protein binding of some of the commonly used cephalosporins on antibacterial activity and several pharmacokinetic parameters are discussed in this communication."( Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations.
Heald, AF; Schreiber, EC; Singhvi, SM, 1978
)
0.26
" The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11."( Cefuroxime: human pharmacokinetics..
Foord, RD, 1976
)
0.26
" Using the values of serum levels obtained from this experiment, pharmacokinetic parameters were calculated and simulation curves of serum levels for various doses and durations of cephaloridine drip infusion were drawn."( [Pharmacokinetics in constant drip infusion of cephaloridine-Lilly (author's transl)].
Fukaya, K; Mashimo, K, 1976
)
0.7
" In a comparative evaluation of nine different cephalosporin antibiotics, not only the objective antibacterial and pharmacokinetic properties are taken into consideration, but also the dosage recommendations of the manufacturers as subjective factors."( [Cephalosporin antibiotics from microbiologic viewpoint. A comparison of antibacterial and pharmacokinetic properties].
Naumann, P, 1975
)
0.25
"The determination of the serum and urine concentrations of cephaloridine permitted calculation of the pharmacokinetic constants of this antibiotic: after administration of a 1-gram intravenous dose in five normal subjects; after administration of a 1-gram intramuscular dose in five normal subjects, five patients with renal impairment and five patients on maintenance hemodialysis."( Adjustment of cephaloridine (Keflodin): dosage according to its pharmacokinetics.
Brandt, C; Brogard, JM; Dammron, A; Dorner, M, 1976
)
0.86
" Based on the pharmacokinetic analysis, the elimination half-life was 32."( Measurement and pharmacokinetic analysis of unbound cephaloridine in rat blood by on-line microdialysis and microbore liquid chromatography.
Chen, CF; Kao, HY; Tsai, TH, 2001
)
0.56
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"We evaluated cefotaxime (CTX) alone and in combination with its metabolite, desacetylcefotaxime (dCTX) against strains of Staphylococcus aureus that produce the four recognized variants of staphylococcal beta-lactamase and a beta-lactamase-producing isolate characterized by the expression of borderline resistance to methicillin."( Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase.
Eades, SC; Kernodle, DS; Stratton, CW; Weeks, LS,
)
0.13
"This study was performed to compare the acute-renal toxicity of azosemide (SK-110) or furosemide (FM) treatment in combination with cephaloridine (CER)."( [Effect of diuretic, azosemide (SK-110), in combination with antibiotic, cephaloridine, on kidney].
Asaeda, N; Ikawa, E; Iwai, H; Koide, M; Nagai, N; Shinoda, M; Tagawa, Y; Tamano, S; Yoshiyasu, T, 1984
)
0.7
" The nephrotoxicity was enhanced by combination with furosemide."( [Nephrotoxicity of piperacillin combined with furosemide in rats].
Aramata, Y; Hori, R; Kizawa, K; Minami, S; Nozawa, I; Shimakura, M; Takahata, M, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The compounds were only poorly absorbed by the oral route in mice, but the 3-(carboxybenzyl) compounds gave more prolonged useful serum levels than the usual cephalosporins."( Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
Basker, MJ; Brain, EG; Eglington, AJ; James, BG; Mizen, LW; Nayler, JH; Osborne, NF; Pearson, MJ; Smale, TC; Southgate, R; Sutherland, R; Tolliday, P, 1977
)
0.26
" The duration of the effective bioavailability of the drugs studied varied from 12 to 18 hours."( Ocular penetration of subconjunctivally injected gentamicin, sisomicin and cephaloridine.
Goyal, M; Jain, MR; Jain, V, 1988
)
0.51
" The very high rate of absorption giving high serum levels and urine concentrations suggest cephalexin will be a useful antibiotic in susceptible bacterial infections in man."( Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic.
Dash, CH; Gower, PE, 1969
)
0.25
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The disposition and dosage regimen of cephaloridine were investigated in healthy calves following a single intramuscular administration of 10 mg/kg. gentamicin in the applied dosage (about 30% of LD50) provoked more pronounced changes than cepHaloridine.

ExcerptRelevanceReference
" The fact that gentamicin in the applied dosage (about 30% of LD50) provoked more pronounced changes than cephaloridine (about 20% of LD50) could be explained by an in-vitro interference of cephaloridine with the enzymatic activities investigated in this study."( Renal effects of gentamicin and cephaloridine. Evaluation by renal enzyme excretion studies in rats and comparison with other antibiotics.
Moerth, C; Raab, W, 1976
)
0.75
"In our study of 54 suspected cases of endophthalmitis, vitreous aspiration was more sensitive in making a culture-proven diagnosis than anterior chamber paracentesis; Staphylococcus epidermidis was a more common cause of endophthalmitis than previously appreciated; and intraocular antibiotics in the recommended dosage are reasonably safe clinically and add a new dimension to the treatment of endophthalmitis."( Further observations on the diagnosis cause, and treatment of endophthalmitis.
Cottingham, AJ; Forster, RK; Norton, EW; Zachary, IG, 1976
)
0.26
"Prophylactic (preventive) antibiotic therapy initiated preoperatively, with antibiotics administered in moderately high dosage for short periods, is recommended on the basis of experimental and prospective, randomized clinical trials for patients who require surgery that is likely to expose tissue planes to contamination."( Prophylactic antibiotic therapy in surgery.
MacLean, LD, 1975
)
0.25
" In a comparative evaluation of nine different cephalosporin antibiotics, not only the objective antibacterial and pharmacokinetic properties are taken into consideration, but also the dosage recommendations of the manufacturers as subjective factors."( [Cephalosporin antibiotics from microbiologic viewpoint. A comparison of antibacterial and pharmacokinetic properties].
Naumann, P, 1975
)
0.25
" Accurate dosage regimens adjusted to the renal status of each individual patient were derived from the calculated values."( Adjustment of cephaloridine (Keflodin): dosage according to its pharmacokinetics.
Brandt, C; Brogard, JM; Dammron, A; Dorner, M, 1976
)
0.62
" Cld did not cause any significant changes in tissue malondialdehyde (MDA) content in vivo at any of the time points examined, but it did cause a depletion of GSH to approximately 40% of control by 1 hr after dosing that recovered toward control by 6 hr."( Cephaloridine-induced renal pathological and biochemical changes in female rabbits and isolated proximal tubules in suspension.
Engelhardt, J; Heim, RA; Ponsler, GD; Rush, GF, 1992
)
1.73
" A dose-response curve was constructed for DQ-2556 inhibition of NMN transport in rat BBMV."( Effect of DQ-2556, a new cephalosporin, on organic ion transport in renal plasma membrane vesicles from the dog, rabbit and rat.
Sokol, PP, 1990
)
0.28
" Diarrhoea occurred in rabbits and monkeys dosed with imipenem or meropenem."( Safety evaluation of meropenem in animals: studies on the kidney.
Goonetilleke, UR; Jones, DV; Murgatroyd, LB; Topham, JC; Wright, J, 1989
)
0.28
"The disposition kinetics and dosage regimen of cephaloridine were investigated in calves following a single intravenous dose of 10 mg."( Disposition kinetics and dosage of cephaloridine in calves.
Chaudhary, RK; Srivastava, AK,
)
0.67
"The disposition and dosage regimen of cephaloridine were investigated in healthy calves following a single intramuscular administration of 10 mg/kg."( Disposition and dosage regimen of cephaloridine in calves.
Chaudhary, RK; Srivastava, AK, 1989
)
0.83
" The recovery of these antibiotics in mixtures of injectable dosage forms is also reported."( Zero-crossing derivative spectrophotometry for the determination of mixtures of cephaloridine and cephalothin in pure and dosage forms.
Morelli, B, 1988
)
0.5
" Each drug was administered single and consecutive 14-day dosage with its alone or in combination with either furosemide or gentamicin."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.27
" The patient's primary physician determined the indications for treatment, and the dosage was uniform for each route of administration."( Double-blind comparison of cephacetrile with cephalothin-cephaloridine.
Daood, M; Jackson, GG; Riff, LJ; Youssuf, M; Zimelis, VM, 1974
)
0.5
" Significant DNA damage was detected up to 14 days after dosing with return to near background levels by 20 days."( Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays.
Clair, JH; DeLuca, JG; Eydelloth, RS; Jensen, RD; Kloss, MW; Kraynak, AR; Nichols, WW; Soper, KA; Storer, RD, 1995
)
0.29
" This increase had a bell-shaped dose-response with a maximum at 500 mg/kg in vivo and 1 mM in vitro."( Impact of cephaloridine on glutathione and related enzymes: comparison of in vivo and in vitro rat models.
Baudelot, A; Bonmarchand, G; Fillastre, JP; Marouillat, S; Monteil, C; Morin, JP; Moritz, F, 1995
)
0.69
" Suggestions are given for a modified dosage schedule in uremic patients and during hemodialysis."( Excretion of cephaloridine and cephalothin in patients with renal impairment.
Atuk, N; Kunin, CM, 1966
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
beta-lactam antibiotic allergenAny beta-lactam antibiotic which causes the onset of an allergic reaction.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
peptidoglycan maturation (meso-diaminopimelate containing)1641

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.18380.003245.467312,589.2998AID2517
aryl hydrocarbon receptorHomo sapiens (human)Potency30.04740.000723.06741,258.9301AID743085; AID743122
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki1,825.00001.60005.744010.0000AID678786; AID681363
Solute carrier family 15 member 1Homo sapiens (human)Ki30,000.00000.18003.39339.8000AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki8,505.68990.79434.22108.0000AID612540
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)1,250.00000.27004.53069.9000AID681331
Solute carrier family 22 member 6Homo sapiens (human)Ki0.74000.03003.20437.8200AID681377
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki8.50003.00006.47788.5000AID681114
Solute carrier family 22 member 8Homo sapiens (human)Ki2.46000.04004.22979.0000AID681373
Solute carrier family 22 member 11Homo sapiens (human)Ki3.63000.20002.57716.1500AID681569
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Ki1,140.00003.09005.54009.1000AID681344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)3.20000.00203.519610.0000AID1215094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Shouchella clausiiKm45.00000.01003.00506.0000AID373209
Beta-lactamase Acinetobacter baumanniiKm100.00003.00005.66679.0000AID567279
Beta-lactamase Klebsiella pneumoniaeKm18.00003.20005.825010.0000AID562754
Beta-lactamase Pseudomonas aeruginosaKm8.00000.30002.00638.0000AID495661
Beta-lactamase Acinetobacter baumanniiKm250.00006.00007.666710.0000AID567280
Beta-lactamaseStaphylococcus aureusKm110.00001.00002.20003.4000AID368313
Beta-lactamaseEnterobacter cloacaeKm375.00002.90006.43649.8000AID368498; AID368523; AID368527; AID495693
Beta-lactamase SHV-1Klebsiella pneumoniaeKm160.00004.20004.25004.3000AID368307; AID495687
Beta-lactamase OXA-10Pseudomonas aeruginosaKm200.00007.90007.90007.9000AID495694
Beta-lactamaseSerratia marcescensKm680.00002.10002.10002.1000AID368725
Beta-lactamasePseudomonas aeruginosa PAO1Km192.40000.50004.24448.0000AID368539; AID368543; AID368547; AID368729; AID495692
Beta-lactamase TEMEscherichia coliKm560.00005.40006.30007.2000AID368309; AID495686
Beta-lactamaseMorganella morganiiKm260.00007.90007.90007.9000AID368531
B2 metallo-beta-lactamase Chryseobacterium indologenesKm90.00003.00003.00003.0000AID562337
Beta-lactamase Klebsiella pneumoniaeKm39.00008.70008.70008.7000AID562755
Efflux transporter Salmonella enterica subsp. enterica serovar NewportKm150.00000.10003.875010.0000AID540966
Beta-lactamase Klebsiella pneumoniaeKm150.00000.10003.02507.3000AID540967
Beta-lactamase Escherichia coliKm290.00000.00461.41494.5000AID495691
Beta-lactamase Serratia marcescensKm400.00002.20004.60008.2000AID368509; AID495696
Beta-lactamase IMP-1 Pseudomonas aeruginosaKm21.00006.50006.50006.5000AID495698
Beta-lactamase Escherichia coliKm39.00007.10008.16678.7000AID368492; AID495688
Carbapenem-hydrolyzing beta-lactamase KPCKlebsiella pneumoniaeKm510.00001.60003.80006.0000AID495695
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm1,062.50002.00006.65009.4000AID368514; AID495697; AID529659; AID531315
Beta-lactamase Acinetobacter baumanniiKm654.80001.30003.80009.6000AID495699; AID495700
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sodium ion transportSolute carrier family 22 member 5Homo sapiens (human)
response to symbiotic bacteriumSolute carrier family 22 member 5Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 5Homo sapiens (human)
carnitine transportSolute carrier family 22 member 5Homo sapiens (human)
response to type II interferonSolute carrier family 22 member 5Homo sapiens (human)
response to tumor necrosis factorSolute carrier family 22 member 5Homo sapiens (human)
positive regulation of intestinal epithelial structure maintenanceSolute carrier family 22 member 5Homo sapiens (human)
sodium-dependent organic cation transportSolute carrier family 22 member 5Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transportSolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 5Homo sapiens (human)
carnitine transmembrane transportSolute carrier family 22 member 5Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 7Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 7Homo sapiens (human)
organic anion transportSolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 7Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingSolute carrier family 22 member 5Homo sapiens (human)
ATP bindingSolute carrier family 22 member 5Homo sapiens (human)
amino-acid betaine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
carnitine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
symporter activitySolute carrier family 22 member 5Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 5Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 5Homo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 7Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cytoplasmSolute carrier family 22 member 5Homo sapiens (human)
endoplasmic reticulumSolute carrier family 22 member 5Homo sapiens (human)
cytosolSolute carrier family 22 member 5Homo sapiens (human)
plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 5Homo sapiens (human)
brush border membraneSolute carrier family 22 member 5Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 5Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
cytosolSolute carrier family 22 member 7Homo sapiens (human)
plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
membraneSolute carrier family 22 member 7Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (317)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1134621Drug level in mouse blood at 50 mg/kg, sc after 10 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID583033Ratio of Kcat to Km for Beta-lactamase AmpC-B22010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1215092Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID680205TP_TRANSPORTER: cell viability in OAT4-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID495699Activity of Pseudomonas aeruginosa SPM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545144Activity of CMY-2 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID529655Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-152008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID562338Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID540966Activity of Salmonella enterica serotype Newport AM17274 cephalosporinase CMY-31 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID495709Kcat/Km ratio of Pseudomonas aeruginosa OXA-102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID522389Activity of Aeromonas caviae Beta-lactamase CAV12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID583034Ratio of Kcat to Km for Beta-lactamase DHA-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID567282Ratio of Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID67856Minimum inhibitory concentration against aerobic organism Enterobacter aerogenes strain 28281982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID162937Minimum inhibitory concentration against aerobic organism Pseudomonas aeruginosa strain 28351982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID495694Activity of Pseudomonas aeruginosa OXA-102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID368543Activity of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID495702Kcat/Km ratio of Klebsiella pneumoniae SHV-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495708Kcat/Km ratio of Enterobacter cloacae AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID368308Ratio of Kcat to Km of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495687Activity of Klebsiella pneumoniae SHV-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID587967Activity of Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID529659Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-22008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID522394Ratio of Kcat Km for Escherichia coli K-12 Beta-lactamase AmpC2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID540968Ratio of Kcat to Km for Salmonella enterica serotype Newport AM17274 cephalosporinase CMY-31 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID529664Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID535720Activity of Escherichia coli TOP10 beta-lactamase AmpC-A2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID368515Ratio of Kcat to Km of Pseudomonas aeruginosa IMP1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID567280Activity of Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID583035Ratio of Kcat to Km for Beta-lactamase CMY-22010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID340888Antimicrobial activity against Escherichia coli JM83 harboring pACYC184-TEM by serial dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID21913Relative hydrolysis rate (RHR) was evaluated against K1 enzyme1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Dependence of beta-lactamase stability on substructures within beta-lactam antibiotics.
AID522393Ratio of Kcat Km for Aeromonas caviae Beta-lactamase CAV12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID340889Antimicrobial activity against Escherichia coli JM83 by serial dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID681234TP_TRANSPORTER: cell viability in OAT3-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID368509Activity of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID373055Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID587986Antibacterial activity against Escherichia coli AS226 after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID495688Activity of Escherichia coli CTX-M-152010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID583021Activity of Beta-lactamase FOX-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID545143Ratio of Kcat to Km for Klebsiella pneumoniae cephalosporinase CMY-36 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID562341Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID495695Activity of Klebsiella pneumoniae KPC-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495690Activity of Klebsiella pneumoniae Beta-lactamase TEM-262010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495691Activity of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1134627Drug level in mouse blood at 50 mg/kg, iv after 10 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID535722Activity of Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID567281Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID368514Activity of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1149738Antibacterial activity against Escherichia coli assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID583022Activity of Beta-lactamase DHA-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID87955Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 15069; Not tested2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID163409Minimum inhibitory concentration against aerobic organism Proteus vulgaris strain 28291982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID373211Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID368497Activity of Klebsiella oxytoca beta-lactamase K1assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID373053Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1134626Drug level in mouse blood at 50 mg/kg, sc after 4 hrs by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID495711Kcat/Km ratio of Serratia marcescens SME-32010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495686Activity of Escherichia coli TEM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495693Activity of Enterobacter cloacae AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID368523Activity of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495696Activity of Serratia marcescens SME-32010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID373050Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID529665Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID368501Activity of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368511Ratio of Kcat to Km of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID535718Activity of Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID587982Antibacterial activity against Escherichia coli AS226 carrying pBSDD240A mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587971Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID679481TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM) in OCTN2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID681377TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID1134625Drug level in mouse blood at 50 mg/kg, sc after 2 hrs by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID525581Activity of Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3)2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Penicillin sulfone inhibitors of class D beta-lactamases.
AID562757Ratio of Kcat to Km for Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID681392TP_TRANSPORTER: uptake in OAT3-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID495692Activity of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID373214Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 to ratio of Kcat/Km for Bacillus anthracis beta-lactamase Bla12007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID368723Ratio of Kcat to Km of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID373210Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID368527Activity of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID681373TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID587966Activity of Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587965Activity of Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID495662Ratio of Kcat to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID368531Activity of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368727Ratio of Kcat to Km of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID680848TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 50 uM, CER: 2500uM) in PEPT1-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID495663Activity at Pseudomonas aeruginosa 51170 beta-lactamase BEL-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID495704Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID495797Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID209245Minimum inhibitory concentration against aerobic organism Streptococcus faecalis strain 28641982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID678869TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 25 uM, CER: 2500uM) in PEPT2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID535717Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B22009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID680337TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID368541Ratio of Kcat to Km of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID583037Activity of Beta-lactamase ACC-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID587973Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID373051Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID422496Activity of Carnobacterium divergens BM4489 penicillinase Cad-1 assessed as initial rate of hydrolysis by spectrophotometer2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID368725Activity of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1149739Antibacterial activity against Salmonella typhi assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID535716Activity of Escherichia coli TOP10 beta-lactamase AmpC-B22009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1134629Drug level in mouse blood at 50 mg/kg, iv after 30 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID529660Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-22008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID535721Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID368498Activity of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID587968Ratio of Kcat to Km for Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587985Antibacterial activity against Escherichia coli AS226 carrying pBSD6 mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID540967Activity of Klebsiella pneumoniae HP205 cephalosporinase CMY-36 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID1134631Drug level in mouse blood at 50 mg/kg, iv after 2 hrs by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID587980Antibacterial activity against Escherichia coli AS226 carrying pBSDS237A mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587960Activity of Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1149736Antibacterial activity against Staphylococcus aureus Oxford assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID587961Activity of Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID587962Activity of Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID87959Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 16043; Not tested2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID587959Activity of Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID21923Compound was evaluated for the relative Vmax against RTEM enzyme1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Dependence of beta-lactamase stability on substructures within beta-lactam antibiotics.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID529663Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1134622Drug level in mouse blood at 50 mg/kg, sc after 20 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID587964Activity of Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID495664Ratio of Kcat to Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID562754Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID495698Activity of Pseudomonas aeruginosa IMP-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681344TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID40467Stability towards penicillinase was determined2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID207836Minimum inhibitory concentration against aerobic organism Staphylococcus aureus strain 28681982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID125411Minimum inhibitory concentration against aerobic organism Morganella morganii strain 28331982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID678786TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID1134623Drug level in mouse blood at 50 mg/kg, sc after 30 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID1149737Antibacterial activity against beta-lactamase producing benzylpenicillin-resistant Staphylococcus aureus Russell assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID368307Activity of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID562755Activity of Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID534394Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID495715Kcat/Km ratio of Acinetobacter baumannii OXA-232010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID583036Ratio of Kcat to Km for Beta-lactamase ACT-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID87957Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 16021; Not tested2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID562337Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID660263Ratio of MIC for wild type Salmonella typhimurium SH5014 to MIC for Salmonella typhimurium SH7616 harboring missense mutation in acrA/acrB gene by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID529661Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID21921Compound was evaluated for the relative Vmax against Escherichia coli with strain 609 (beta-Lactamase-positive (LAC+)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Dependence of beta-lactamase stability on substructures within beta-lactam antibiotics.
AID1134632Drug level in mouse blood at 50 mg/kg, iv after 4 hrs by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID495710Kcat/Km ratio of Klebsiella pneumoniae KPC-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1149740Antibacterial activity against Shigella sonnei assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID529666Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID522390Activity of Escherichia coli K-12 Beta-lactamase AmpC2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID368731Ratio of Kcat to Km of Pseudomonas aeruginosa AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495661Activity at Pseudomonas aeruginosa 531 beta-lactamase BEL-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID1215091Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID368494Ratio of Kcat to Km of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID373209Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID495697Activity of Pseudomonas aeruginosa VIM-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID422498Ratio of Kcat to Km of Carnobacterium divergens BM4489 penicillinase Cad-1 relative to benzyl-penicillin2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID587969Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587979Antibacterial activity against Escherichia coli AS226 carrying pBSDN104D mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID495712Kcat/Km ratio of Pseudomonas aeruginosa VIM-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID368547Activity of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID373213Ratio of Kcat to Km for Bacillus anthracis beta-lactamase Bla12007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID681363TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID529657Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-162008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID562756Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID368505Activity of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID162882Minimum inhibitory concentration against aerobic organism Proteus mirabilis strain 28301982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID525582Ratio of Kcat to Km for Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3)2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Penicillin sulfone inhibitors of class D beta-lactamases.
AID368309Activity of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368521Ratio of Kcat to Km of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID681569TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT4-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID422497Ratio of Kcat to Km of Carnobacterium divergens BM4489 penicillinase Cad-12008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID368539Activity of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495713Kcat/Km ratio of Pseudomonas aeruginosa IMP-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID207394Minimum inhibitory concentration against aerobic organism Staphylococcus aureus strain 28651982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID368533Ratio of Kcat to Km of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID495798Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID583032Ratio of Kcat to Km for Beta-lactamase ACC-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID368313Activity of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368503Ratio of Kcat to Km of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1134628Drug level in mouse blood at 50 mg/kg, iv after 20 mins by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID583023Activity of Beta-lactamase ACT-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID535719Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID587963Activity of Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID567279Activity of Acinetobacter baumannii ADC-33 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID679549TP_TRANSPORTER: cell viability in OAT1-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID587976Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID368537Ratio of Kcat to Km of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID522388Activity of Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID545145Ratio of Kcat to Km of CMY-2 by spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID587975Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID21914Relative hydrolysis rate (RHR) was evaluated against RTEM enzyme1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Dependence of beta-lactamase stability on substructures within beta-lactam antibiotics.
AID495700Activity of Acinetobacter baumannii OXA-232010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534396Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID368729Activity of Pseudomonas aeruginosa AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID340887Antimicrobial activity against Escherichia coli JM83 harboring pACYC184-ATEM by serial dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID69322MIC against aerobic organism Escherichia coli strain 28911982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID587983Antibacterial activity against Escherichia coli AS226 carrying pBSDC69A mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID43102The compound was tested against Bacteroides fragilis FP784 and its stability towards beta-lactamase relative to cephaloridine was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID587972Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID43103The compound was tested against Bacteroides fragilis FP784 its stability towards beta-lactamase relative to cephaloridine was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID567283Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID40355Relative stability towards penicillinase was determined2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID1149742Antibacterial activity against Proteus mirabilis assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID583039Activity of Beta-lactamase CMY-22010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID583038Activity of Beta-lactamase AmpC-B22010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID495714Kcat/Km ratio of Pseudomonas aeruginosa SPM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529662Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID678797TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID368490Ratio of Kcat to Km of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535723Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID368517Ratio of Kcat to Km of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368545Ratio of Kcat to Km of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID93880Minimum inhibitory concentration against aerobic organism Klebsiella pneumoniae strain 40051982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID495707Kcat/Km ratio of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID326270Activity of Escherichia coli beta-lactamase SCO1 relative to penicillin G2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID68516Minimum inhibitory concentration against aerobic organism Enterobacter cloacae strain 26461982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID587970Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587984Antibacterial activity against Escherichia coli AS226 carrying pBSDF160T mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID495689Activity of Klebsiella oxytoca Beta-lactamase K12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID373052Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID40353Relative stability towards beta-lactamase was determined in Bacillus fragilis FP7842004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID373054Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID495706Kcat/Km ratio of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID680338TP_TRANSPORTER: uptake in OAT1-expressing S3 cells1999Kidney international, Dec, Volume: 56, Issue:6
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
AID587978Antibacterial activity against Escherichia coli AS226 carrying pBSDN104A mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID678819TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID326271Activity of Escherichia coli K12 beta-lactamase CARB1 relative to penicillin G2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID680409TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, CER: 1000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID495705Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-262010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID368525Ratio of Kcat to Km of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1134624Drug level in mouse blood at 50 mg/kg, sc after 1 hr by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID368535Activity of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID587977Antibacterial activity against Escherichia coli AS226 carrying pBSD-H2 after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1134630Drug level in mouse blood at 50 mg/kg, iv after 1 hr by microbiological assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID368499Ratio of Kcat to Km of Klebsiella oxytoca beta-lactamase K1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID156435The compound was tested against Penicillinase (TEM) and its stability towards beta-lactamase relative to cephaloridine was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID40359Stability towards beta-lactamase was determined in penicillinase2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID522392Ratio of Kcat Km for Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID1149741Antibacterial activity against Klebsiella aerogenes assessed as growth inhibition after 18 hrs by serial dilution method1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Structure--activity relationships in cephalosporins prepared from penicillins. 1. 7beta-Acylamino derivatives of 3-benzyl- and 3-(3-pyridylmethyl)ceph-3-em-4-carboxylic acids.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID529658Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-162008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID368312Ratio of Kcat to Km of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID587974Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID495703Kcat/Km ratio of Escherichia coli CTX-M-152010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID40357Stability towards beta-lactamase was determined in Bacillus fragilis FP7842004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID40465Stability towards beta-lactamase was determined in Bacillus fragilis FP7842004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID326272Activity of Escherichia coli K12 beta-lactamase TEM1 relative to penicillin G2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID368492Activity of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID43101The compound was tested against Bacteroides fragilis FP784 and its stability towards beta-lactamase was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID368507Ratio of Kcat to Km of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID682253TP_TRANSPORTER: uptake in OCTN2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID587981Antibacterial activity against Escherichia coli AS226 carrying pBSDD240S mutant after 18 hrs by broth microdilution method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID495701Kcat/Km ratio of Escherichia coli TEM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID583031Ratio of Kcat to Km for Beta-lactamase FOX-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID529656Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-152008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID156429The compound was tested against Penicillinase (TEM) and its stability towards beta-lactamase was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID368529Ratio of Kcat to Km of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID200341Minimum inhibitory concentration against aerobic organism Salmonella strain 38601982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID156432The compound was tested against Penicillinase (TEM) and its stability towards beta-lactamase relative to cephaloridine was evaluated1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,461)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901301 (89.05)18.7374
1990's80 (5.48)18.2507
2000's56 (3.83)29.6817
2010's23 (1.57)24.3611
2020's1 (0.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.45 (24.57)
Research Supply Index7.41 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials110 (7.11%)5.53%
Reviews44 (2.84%)6.00%
Case Studies34 (2.20%)4.05%
Observational0 (0.00%)0.25%
Other1,359 (87.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]